Survival and drug resistance mechanisms of ovarian carcinoma cells in effusions
Survival and drug resistance mechanisms of ovarian cancer
This project, kindly supported by Helse Sør-Øst is progressing as planned, with good scientific production. In addition to the above paper published in Cancer, 3 publications acknowledging the contribution of Helse Sør-Øst are in press, 1 is submitted, and 1 will be submitted this week. Several more are under preparation
The in press/submitted papers are the following:
1. Dong HP, Kleinberg L, Davidson B, Risberg B. Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by Flow Cytometry. In press, Nat Protocol
2. Davidson B, Shih IeM, Wang TL. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. In press, Hum Pathol
3. Kleinberg L, Pradhan M, Trope' CG, Nesland JM, Davidson D, Risberg B. Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors. In press, Diagn Cytopathol
4. Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B. The diagnostic and prognostic role of the insulin growth factor pathway members IGF-II and IGFBP3 in serous effusions. Submitted to Cancer
The progress with respect to the areas we applied for in our grant proposal is as follows:
1. High-throughput studies in collaboration with Johns Hopkins University:
The proteomic analysis in collaboration with Johns Hopkins University is completed, paper in writing.
The SNP array analysis is currently performed with Prof. Jean-Paul Thierry, formerly at the Curie Institute in Paris, currently Deputy Director at IMCB ASTAR PROTEOS, SINGAPORE. It will be completed in the course of 2008.
Paper 2 in the in press list is also in collaboration with Johns Hopkins, and Paper 4 in this list is based on previous results with Johns Hopkins group.
2. High-throughput studies using the Affymetrix arrays (in house project):
The Affymetrix analysis has been completed and the data analyzed. We are currently validating the findings using other methods. Expected to be completed in 2008.
3. Analysis of mechanisms mediating apoptosis and chemoresistance in cancer cells in effusions (PhD projects of Lilach Kleinberg and Hiep Phuc Dong):
This project generated the Cancer paper, as well as papers 1 and 3 in the in press list. An additional paper will be submitted this week, and more work is underway.
I use the opportunity to thank Helse Sør-Øst again for their generous support.
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma.
Cancer 2008 Jan;112(1):84-93.